Citadel Advisors’s Evotec EVO Stock Holding History

Citadel Advisors’s Portfolio EVO Stock Details EVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$218K	Buy	87,180 +17,665	+25%	+$56.9K	﹤0.01%	11245
2025 Q4	$214K	Sell	69,515 -26,530	-28%	-$91K	﹤0.01%	10900
2025 Q3	$349K	Buy	96,045 +62,471	+186%	+$237K	﹤0.01%	10012
2025 Q2	$141K	Buy	+33,574	New	+$132K	﹤0.01%	11012
2024 Q4	–	Sell	-27,460	Closed	-$100K	–	14736
2024 Q3	$100K	Buy	27,460 +16,016	+140%	+$63.5K	﹤0.01%	11113
2024 Q2	$54.9K	Buy	+11,444	New	+$64.2K	﹤0.01%	11654
2023 Q4	–	Sell	-25,754	Closed	-$254K	–	14529
2023 Q3	$254K	Buy	25,754 +12,254	+91%	+$144K	﹤0.01%	9472
2023 Q2	$151K	Buy	+13,500	New	+$144K	﹤0.01%	10324
2023 Q1	–	Sell	-13,284	Closed	-$107K	–	14909
2022 Q4	$107K	Buy	+13,284	New	+$116K	﹤0.01%	11117

Other funds holding EVO

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Citadel Advisors's EVO Position: Q1 2026 in Review

Citadel Advisors increased its Evotec (EVO) stake by 25% in Q1 2026, buying an estimated $56.9K and bringing the position to 87,180 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #11245.

Citadel Advisors first reported a position in EVO in Q4 2022 and has held it in 9 quarters since. The position peaked at $349K in Q3 2025. 46 funds tracked by Wall St. Rank hold EVO as of Q1 2026.

Citadel Advisors held 87,180 shares of Evotec worth $218K as of Q1 2026.
Citadel Advisors bought 17,665 Evotec shares in Q1 2026, an estimated $56.9K.
Evotec made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11245 holding.
Citadel Advisors first reported a position in Evotec in Q4 2022 and has held it in 9 quarters since.
Citadel Advisors's Evotec position peaked at $349K in Q3 2025.
46 funds tracked by Wall St. Rank held Evotec as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.